Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study
© 2021. The Author(s)..
BACKGROUND: Low adherence to investigational products can negatively impact study outcomes, limiting the ability to demonstrate efficacy. To continue advancing potential new HIV prevention technologies, efforts are needed to improve adherence among study participants. In MTN-020/ASPIRE, a phase III randomized, double-blind, placebo-controlled study of the dapivirine vaginal ring carried out across 15 sites in sub-Saharan Africa, a multifaceted approach to adherence support was implemented, including a strong focus on participant engagement activities (PEAs). In this manuscript, we describe PEAs and participant attendance, and analyze the potential impact of PEAs on ring use.
METHODS: All sites implemented PEAs and submitted activity and attendance reports to the study management team throughout the study. Participant demographics were collected via case report forms. Residual dapivirine remaining in the last ring returned by each participant was used to estimate drug released from the ring, which was then adjusted for time participants had the ring to calculate probable use categorized into three levels (low/intermittent/high). Product use was connected to PEA attendance using participant identification numbers. We used multivariate Poisson regression with robust standard errors to explore differences in ring use between PEA attendance groups and reviewed qualitative reports for illustrative quotes highlighting participant experiences with PEAs.
RESULTS: 2312 of 2629 study participants attended at least one of 389 PEAs conducted across sites. Participant country and partner knowledge of study participation were most strongly associated with PEA attendance (p < 0.005) with age, education, and income status also associated with event attendance (p < 0.05). When controlling for these variables, participants who attended at least one event were more likely to return a last ring showing at least some use (RR = 1.40) than those who never attended an event. There was a stronger correlation between a last returned ring showing use and participant attendance at multiple events (RR = 1.52).
CONCLUSIONS: Our analysis supports the growing body of work illustrating the importance of meaningfully engaging research participants to achieve study success and aligns with other analyses of adherence support efforts during ASPIRE. While causation between PEA attendance and product use cannot be established, residual drug levels in returned rings strongly correlated with participant attendance at PEAs, and the benefits of incorporating PEAs should be considered when designing future studies of investigational products.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
BMC public health - 21(2021), 1 vom: 08. Nov., Seite 2041 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Garcia, Morgan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adherence |
|---|
| Anmerkungen: |
Date Completed 06.12.2021 Date Revised 24.09.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12889-021-11919-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332877019 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332877019 | ||
| 003 | DE-627 | ||
| 005 | 20231225220459.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12889-021-11919-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332877019 | ||
| 035 | |a (NLM)34749675 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garcia, Morgan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2021 | ||
| 500 | |a Date Revised 24.09.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a BACKGROUND: Low adherence to investigational products can negatively impact study outcomes, limiting the ability to demonstrate efficacy. To continue advancing potential new HIV prevention technologies, efforts are needed to improve adherence among study participants. In MTN-020/ASPIRE, a phase III randomized, double-blind, placebo-controlled study of the dapivirine vaginal ring carried out across 15 sites in sub-Saharan Africa, a multifaceted approach to adherence support was implemented, including a strong focus on participant engagement activities (PEAs). In this manuscript, we describe PEAs and participant attendance, and analyze the potential impact of PEAs on ring use | ||
| 520 | |a METHODS: All sites implemented PEAs and submitted activity and attendance reports to the study management team throughout the study. Participant demographics were collected via case report forms. Residual dapivirine remaining in the last ring returned by each participant was used to estimate drug released from the ring, which was then adjusted for time participants had the ring to calculate probable use categorized into three levels (low/intermittent/high). Product use was connected to PEA attendance using participant identification numbers. We used multivariate Poisson regression with robust standard errors to explore differences in ring use between PEA attendance groups and reviewed qualitative reports for illustrative quotes highlighting participant experiences with PEAs | ||
| 520 | |a RESULTS: 2312 of 2629 study participants attended at least one of 389 PEAs conducted across sites. Participant country and partner knowledge of study participation were most strongly associated with PEA attendance (p < 0.005) with age, education, and income status also associated with event attendance (p < 0.05). When controlling for these variables, participants who attended at least one event were more likely to return a last ring showing at least some use (RR = 1.40) than those who never attended an event. There was a stronger correlation between a last returned ring showing use and participant attendance at multiple events (RR = 1.52) | ||
| 520 | |a CONCLUSIONS: Our analysis supports the growing body of work illustrating the importance of meaningfully engaging research participants to achieve study success and aligns with other analyses of adherence support efforts during ASPIRE. While causation between PEA attendance and product use cannot be established, residual drug levels in returned rings strongly correlated with participant attendance at PEAs, and the benefits of incorporating PEAs should be considered when designing future studies of investigational products | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Adherence | |
| 650 | 4 | |a Dapivirine | |
| 650 | 4 | |a HIV prevention | |
| 650 | 4 | |a Microbicides | |
| 650 | 4 | |a Participant engagement | |
| 650 | 4 | |a PrEP | |
| 650 | 4 | |a Ring | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Dapivirine |2 NLM | |
| 650 | 7 | |a TCN4MG2VXS |2 NLM | |
| 700 | 1 | |a Luecke, Ellen |e verfasserin |4 aut | |
| 700 | 1 | |a Mayo, Ashley J |e verfasserin |4 aut | |
| 700 | 1 | |a Scheckter, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Ndase, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Kiweewa, Flavia Matovu |e verfasserin |4 aut | |
| 700 | 1 | |a Kemigisha, Doreen |e verfasserin |4 aut | |
| 700 | 1 | |a Musara, Petina |e verfasserin |4 aut | |
| 700 | 1 | |a Mansoor, Leila E |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Nishanta |e verfasserin |4 aut | |
| 700 | 1 | |a Woeber, Kubashni |e verfasserin |4 aut | |
| 700 | 1 | |a Morar, Neetha S |e verfasserin |4 aut | |
| 700 | 1 | |a Jeenarain, Nitesha |e verfasserin |4 aut | |
| 700 | 1 | |a Gaffoor, Zakir |e verfasserin |4 aut | |
| 700 | 1 | |a Gondwe, Daniel K |e verfasserin |4 aut | |
| 700 | 1 | |a Makala, Yvonne |e verfasserin |4 aut | |
| 700 | 1 | |a Fleurs, Llewellyn |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, Krishnaveni |e verfasserin |4 aut | |
| 700 | 1 | |a Palanee-Phillips, Thesla |e verfasserin |4 aut | |
| 700 | 1 | |a Baeten, Jared M |e verfasserin |4 aut | |
| 700 | 1 | |a van der Straten, Ariane |e verfasserin |4 aut | |
| 700 | 1 | |a Soto-Torres, Lydia |e verfasserin |4 aut | |
| 700 | 1 | |a Torjesen, Kristine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC public health |d 2001 |g 21(2021), 1 vom: 08. Nov., Seite 2041 |w (DE-627)NLM111200962 |x 1471-2458 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:1 |g day:08 |g month:11 |g pages:2041 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12889-021-11919-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 1 |b 08 |c 11 |h 2041 | ||